On ECHEMI
Home > Drugs > Shenyang Shenlong Pharmaceutical Co., Ltd.
Shenyang Shenlong Pharmaceutical Co., Ltd.
  • Founded in:

    1998-07-19
  • Country:

    China China
  • Address:

    No. 9, Jinhui Street, Hunnan New District, Shenyang
  • Tax NO.:

    912101127209312097
  • Registered Funds:

    5 million yuan
  • Website:

  • Email:

Related Drugs
Xuesetong Injection
Total saponins of Panax notoginseng.
Name Description Content CAS NO. Registered Holders
Panax notoginsenosides

It has anti-cerebral ischemia effect, can improve brain edema in rats with multiple cerebral infarction, promote glial cell reaction, accelerate the absorption and organization of softening foci, and reduce neuronal lesions in the hippocampus; it has a protective effect on delayed neuronal damage in the hippocampus of gerbils with transient cerebral ischemia, can reduce the Ca2 content in brain tissue after ischemia, reduce the number of dead neurons, and increase neuronal density. It has anti-myocardial ischemia effect, can reduce the downward shift of the electrocardiogram S-T segment of acute myocardial ischemia in rats, and adjust the electrocardiogram inhomogeneity. It improves blood rheology, can reduce whole blood viscosity and plasma viscosity, reduce hematocrit and platelet aggregation rate, slow down erythrocyte sedimentation rate, and reduce fibrinogen content. It improves microcirculation effect, can reduce the microcirculation morphological integral, flow integral, semi-circular integral, and overall integral of the nail fold microcirculation, reduce loop exudation, reduce tube diameter, increase flow velocity, reduce red blood cell aggregation, reduce loop top congestion, increase loop clarity, and subside edema. It has the effect of lowering blood lipids, reducing total cholesterol and triglycerides, and reducing serum triglycerides, cholesterol and low-density lipoprotein levels. It has the effect of resisting free radical damage, increasing the activity of erythrocyte superoxide dismutase, reducing plasma malondialdehyde content, and reducing serum protein kinase C and aspartate aminotransferase levels.

More

It has anti-cerebral ischemia effect, can improve brain edema in rats with multiple cerebral infarction, promote glial cell reaction, accelerate the absorption and organization of softening foci, and reduce neuronal lesions in the hippocampus; it has a protective effect on delayed neuronal damage in the hippocampus of gerbils with transient cerebral ischemia, can reduce the Ca2 content in brain tissue after ischemia, reduce the number of dead neurons, and increase neuronal density. It has anti-myocardial ischemia effect, can reduce the downward shift of the electrocardiogram S-T segment of acute myocardial ischemia in rats, and adjust the electrocardiogram inhomogeneity. It improves blood rheology, can reduce whole blood viscosity and plasma viscosity, reduce hematocrit and platelet aggregation rate, slow down erythrocyte sedimentation rate, and reduce fibrinogen content. It improves microcirculation effect, can reduce the microcirculation morphological integral, flow integral, semi-circular integral, and overall integral of the nail fold microcirculation, reduce loop exudation, reduce tube diameter, increase flow velocity, reduce red blood cell aggregation, reduce loop top congestion, increase loop clarity, and subside edema. It has the effect of lowering blood lipids, reducing total cholesterol and triglycerides, and reducing serum triglycerides, cholesterol and low-density lipoprotein levels. It has the effect of resisting free radical damage, increasing the activity of erythrocyte superoxide dismutase, reducing plasma malondialdehyde content, and reducing serum protein kinase C and aspartate aminotransferase levels.

0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.